摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

伊菠胺 | 481-87-8

中文名称
伊菠胺
中文别名
——
英文名称
ibogamine
英文别名
Ibogamin;(1R,15R,17S,18S)-17-ethyl-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene
伊菠胺化学式
CAS
481-87-8
化学式
C19H24N2
mdl
——
分子量
280.413
InChiKey
LRLCVRYKAFDXKU-YGOSVGOTSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    162-164 °C
  • 沸点:
    452.2±35.0 °C(Predicted)
  • 密度:
    1.18±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    21
  • 可旋转键数:
    1
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.58
  • 拓扑面积:
    19
  • 氢给体数:
    1
  • 氢受体数:
    1

SDS

SDS:59b18ec96475db49de4c0633fd2ccf65
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] SMALL MOLECULE INDUCERS OF GDNF AS POTENTIAL NEW THERAPEUTICS FOR NEUROPSYCHIATRIC DISORDERS<br/>[FR] PETITES MOLÉCULES INDUCTRICES DE GDNF COMME NOUVELLE THÉRAPEUTIQUE POSSIBLE DES TROUBLES NEUROPSYCHIATRIQUES
    申请人:UNIV COLUMBIA
    公开号:WO2013028999A1
    公开(公告)日:2013-02-28
    The invention provides a compound having the structure (I), wherein A is a substituted or unsubstituted ring; Z is present or absent and when present is (II), wherein n is 0, 1, 2, 3, or 4; Y is -(CR11R12)-, -NH(CR11R12)- or -O(CR11R12)- wherein R11 and R12 are each hydrogen or combine to form a carbonyl; and wherein R1 to R10 are herein as described.
    本发明提供了一种具有结构(I)的化合物,其中A是取代的或未取代的环;Z是否存在,如果存在则为(II),其中n为0,1,2,3或4;Y是-(CR11R12)-,-NH(CR11R12)-或-O(CR11R12)-,其中R11和R12分别是氢或结合形成一个羰基;以及其中R1至R10如本文所述。
  • Constructing <i>Iboga</i> Alkaloids via C–H Bond Functionalization: Examination of the Direct and Catalytic Union of Heteroarenes and Isoquinuclidine Alkenes
    作者:Andrew C. Kruegel、Souvik Rakshit、Xiaoguang Li、Dalibor Sames
    DOI:10.1021/jo5018102
    日期:2015.2.20
    The iboga alkaloids have attracted considerable attention in both the scientific community and popular media due to their reported ability to reverse or markedly diminish cravings for, and self-administration of, the major drugs of abuse. We have developed three new intramolecular C–H functionalization procedures leading to the core seven-membered ring of the iboga skeleton, a cyclization that proved
    由于据报道,伊博加生物碱具有逆转或显着减少对主要滥用药物的渴望和自我管理的能力,因此在科学界和大众媒体中都引起了相当大的关注。我们已经开发了三种新的分子内C–H功能化程序,这些程序导致了iboga骨架的核心七元环,这种环化过程极具挑战性。亲电钯盐Pd(CH 3 CN)4(BF 4)2对多种N-(2-芳基乙基)异喹核苷,收率为10–35%。两步溴化还原型Heck反应方案对于以42%的产率合成ibogamine也是有效的。最后,直接的Ni(0)催化的C–H功能化提供了ibogamine(74%)和epi- ibogamine(38%)的苯并呋喃类似物。尽管每种方法都有明显的缺点,但结合起来,所描述的方法提供了通往各种异烟酰胺类似物的实用途径。
  • Reductive Heck coupling: an efficient approach toward the iboga alkaloids. Synthesis of ibogamine, epiibogamine and iboga analogs
    作者:Goutam Kumar Jana、Surajit Sinha
    DOI:10.1016/j.tetlet.2012.01.097
    日期:2012.3
    A mild and efficient synthetic route to the iboga scaffold by employing reductive-Heck type annulation is described. The utility of this process is demonstrated by the direct access to the ibogamine, epiibogamine and iboga-analogs. The cyclization precursors were readily obtained from 2-iodoaniline by heteroannulation reaction with suitable alkynes followed by iodination.
    描述了通过采用还原性-Heck型环化法制备iboga支架的温和而有效的合成途径。该方法的实用性通过直接接触伊布巴明,表异巴胺和依博加类似物得到证明。通过与合适的炔烃进行异环反应,然后进行碘化,可以容易地从2-碘苯胺获得环化前体。
  • DIVERSITY-ORIENTED SYNTHESIS OF N,N,O-TRISUBSTITUTED HYDROXYLAMINES FROM ALCOHOLS AND AMINES BY N-O BOND FORMATION
    申请人:University of Georgia Research Foundation, Inc.
    公开号:US20210363098A1
    公开(公告)日:2021-11-25
    In one aspect, the disclosure relates to a method for the direct synthesis of complex N,N,O-trisubstituted hydroxylamines by N—O bond formation. In another aspect, the method can successfully be employed using a wide variety of commercially available alcohols and secondary amines and enables the construction of large fragment-based libraries of trisubstituted hydroxylamines for drug discovery purposes. Also disclosed are N,N,O-trisubstituted hydroxylamines having low basicity, high stability at ambient temperatures, and an inherent lack of reactivity towards acetylating and sulfonylating enzymes that confer mutagenicity on less-substituted hydroxylamines.
    在一个方面,该公开涉及一种通过N-O键形成直接合成复杂的N,N,O-三取代羟胺的方法。在另一个方面,该方法可以成功地利用各种商业可用的醇和二级胺,并实现构建基于大片段的三取代羟胺文库,用于药物发现目的。还公开了具有低碱性、在常温下高稳定性和固有缺乏对乙酰化和磺酰化酶的反应性的N,N,O-三取代羟胺,这些酶使得较少取代的羟胺具有致突变性。
  • Catalyzed Asymmetric Diels−Alder Reaction of Benzoquinone. Total Synthesis of (−)-Ibogamine
    作者:James D. White、Younggi Choi
    DOI:10.1021/ol0001463
    日期:2000.7.1
    The Diels-Alder addition of diene 2 with benzoquinone catalyzed by (S)-BINOL-TiCl(2) produced cycloadduct 5 in >65% yield and 87% ee. The cycloadduct was transformed into (-)-ibogamine in nine steps (10% overall yield from benzoquinone). A model for the transition state leading to 5 is proposed.
    由(S)-BINOL-TiCl(2)催化的二烯2与苯醌的Diels-Alder加成反应产生环加合物5,收率> 65%,ee为87%。通过九个步骤将环加合物转化为(-)-异烟酰胺(苯醌的总产率为10%)。提出了导致5的过渡态模型。
查看更多

同类化合物

马山茶碱 非洲伏康树碱 长春质碱 老刺木任 硫酸长春质碱 海尼山辣椒碱羟基假吲哚 榴花碱 柳黄酸 伏康京碱 伊菠胺-18-羧酸甲酯 伊菠胺 伊菠加因盐酸盐 伊博格碱 7-羟基-1-去氢老刺木碱 20-羟基榴花碱 14-((3alpha)-17-甲氧基-17-氧代派利文碱-3-基)-伊菠胺-18-羧酸甲酯 13-甲氧基-14-[(3A)-17-甲氧基-17-氧代派利文碱-3-基]-伊菠胺-18-羧酸甲酯 13-甲氧基-12-[(3a)-17-甲氧基-17-氧代派利文碱-3-基]-伊菠胺-18-羧酸甲酯 12-((3alpha)-17-甲氧基-17-氧代派利文碱-3-基)-伊菠胺-18-羧酸甲酯 11-羟基狗牙花定 10-羟基狗牙花定 (4a,20S)-20-羟基伊菠胺-18-羧酸甲酯 (2S)-1,2,3,4,4abeta,5,6,7,7a,12bbeta-十氢-4alpha-(1-羟基乙基)-9-甲氧基-2alpha,5alpha-甲桥吲哚并[3,2-d][1]苯并氮杂卓-7alpha-醇 epiibogaine N-methylcatharanthine quaternary salt lauryl albifloranine (+/-)-Coronaridine 18-methoxycoronaridine hydrochloride voacangine 19-Ethoxycoronaridin N-methylibogaine 2-(dimethylamino)ethyl (1R,15R,17S,18S)-17-ethyl-7-hydroxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene-3-carboxylate ethyl (1R,15R,17S,18S)-17-ethyl-7-hydroxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene-3-carboxylate [(1R,15R,17S,18S)-3-dimethoxyphosphoryl-17-ethyl-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraen-7-yl] 4-methylpiperazine-1-carboxylate hydron;methyl (1S,15R,17S,18S)-17-ethyl-14-hydroxy-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene-1-carboxylate;chloride eglandine Ibogamine-18-carboxylic acid, 19-hydroxy-12-methoxy-, methyl ester, (19R)- 3-(beta-Hydroxyethyl)coronaridine Ibogamine-18-carboxylic acid, 13,20-dihydroxy-, methyl ester, (4alpha,20S)- 10-Hydroxyheyneanine Ibogamine-18-carboxylic acid, 21-hydroxy-, methyl ester Ibogamin-20-ol, 8,19-epoxy-12-methoxy-, (4alpha,8beta,19S,20S)- Voacangine Conopharyngine ibogaline (+/-)-coronaridine (-)-Ibogaine (15S,17R)-17-ethyl-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4,6,8-tetraene (15S,17R)-17-ethyl-7-methoxy-3-methyl-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraene Voacangine 11-(3,4-dimethoxybenzyl)